Cost-Benefit Analysis of Antimicrobial Stewardship Program in the Adult General Medicine Setting in Qatar
<h3>Background</h3><p dir="ltr">There is a lack of evidence regarding the economic impact of antimicrobial stewardship program (ASP).We sought to evaluate the cost-benefit of the mature ASP use compared to premature ASP use in the adults’ general medicine settings in Qata...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513514069032960 |
|---|---|
| author | Dina Abushanab (10696501) |
| author2 | Wafa Al-Maridi (18472441) Moza Al Hail (2511859) Palli Valappila Abdul Rouf (18472392) Wessam El Kassem (5801975) Binny Thomas (5801969) Hussam Alsoub (14777305) Zanfina Ademi (3420128) Yolande Hanssens (14151507) Rasha El Enany (18472442) Daoud Al-Badriyeh (832403) |
| author2_role | author author author author author author author author author author |
| author_facet | Dina Abushanab (10696501) Wafa Al-Maridi (18472441) Moza Al Hail (2511859) Palli Valappila Abdul Rouf (18472392) Wessam El Kassem (5801975) Binny Thomas (5801969) Hussam Alsoub (14777305) Zanfina Ademi (3420128) Yolande Hanssens (14151507) Rasha El Enany (18472442) Daoud Al-Badriyeh (832403) |
| author_role | author |
| dc.creator.none.fl_str_mv | Dina Abushanab (10696501) Wafa Al-Maridi (18472441) Moza Al Hail (2511859) Palli Valappila Abdul Rouf (18472392) Wessam El Kassem (5801975) Binny Thomas (5801969) Hussam Alsoub (14777305) Zanfina Ademi (3420128) Yolande Hanssens (14151507) Rasha El Enany (18472442) Daoud Al-Badriyeh (832403) |
| dc.date.none.fl_str_mv | 2024-05-26T10:59:37Z |
| dc.identifier.none.fl_str_mv | 10.57945/manara.25709292.v1 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/conference_contribution/Cost-Benefit_Analysis_of_Antimicrobial_Stewardship_Program_in_the_Adult_General_Medicine_Setting_in_Qatar/25709292 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Pharmacology and pharmaceutical sciences Economics Applied economics Antimicrobial Stewardship Cost-benefit General medicine Qatar Qatar Health Congress 2023 and the 3rd Qatar Public Health Conference |
| dc.title.none.fl_str_mv | Cost-Benefit Analysis of Antimicrobial Stewardship Program in the Adult General Medicine Setting in Qatar |
| dc.type.none.fl_str_mv | Text Conference contribution info:eu-repo/semantics/publishedVersion text conference object |
| description | <h3>Background</h3><p dir="ltr">There is a lack of evidence regarding the economic impact of antimicrobial stewardship program (ASP).We sought to evaluate the cost-benefit of the mature ASP use compared to premature ASP use in the adults’ general medicine settings in Qatar. </p><h3>Methods</h3><p dir="ltr">Patient records were retrospectively reviewed during two periods: premature ASP (i.e. the 12 months following ASP implementation (May 2015-April 2016)), and mature ASP (i.e. the last 12 months of a 5-year ASP implementation in Hamad Medical Corporation (HMC) (February 2019-January 2020)). The economic benefit of the ASP maturity was calculated as the sum of the cost savings and the cost avoidance, minus the operational cost of the service.3 The cost savings were the reduced cost of therapy associated with an assumed reduction in defined daily dose and resource utilization because of the ASP maturity. Cost avoidance was the cost avoided by reducing length of hospitalization and adverse drug events. Operational costs included the monetary value of the time spent in data collection, clinical rounds, and committee meetings. A total of 500 patients were randomly included (250 in each cohort).</p><h3> Results</h3><p dir="ltr">The operational costs of the program decreased with maturity by cost savings of QAR125 per 100-patient beds per year. Antimicrobials use and resource utilization, and their associated costs, declined after the maturity of ASP (i.e. positive cost saving), with a cost saving of QAR 458 (US$ 125) per 100-patient beds per year, signifying a benefit of QAR 458 generated for each QAR 1 invested in the ASP service. The avoided cost was in negative, by QAR -4,807 per 100-patient beds, in favour of the premature period. Sensitivity analyses indicated a 100% probability that maturity is linked with a positive benefit-to-cost ratio (Figures 1 and 2).</p><h3>Conclusion</h3><p dir="ltr">We showed that substantial savings in healthcare costs can be achieved through the maturity of ASP, even when accounting for ASP operational costs.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_40edae4ebc73faeb635c657a373dbaab |
| identifier_str_mv | 10.57945/manara.25709292.v1 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25709292 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Cost-Benefit Analysis of Antimicrobial Stewardship Program in the Adult General Medicine Setting in QatarDina Abushanab (10696501)Wafa Al-Maridi (18472441)Moza Al Hail (2511859)Palli Valappila Abdul Rouf (18472392)Wessam El Kassem (5801975)Binny Thomas (5801969)Hussam Alsoub (14777305)Zanfina Ademi (3420128)Yolande Hanssens (14151507)Rasha El Enany (18472442)Daoud Al-Badriyeh (832403)Biomedical and clinical sciencesClinical sciencesPharmacology and pharmaceutical sciencesEconomicsApplied economicsAntimicrobialStewardshipCost-benefitGeneral medicineQatarQatar Health Congress 2023 and the 3rd Qatar Public Health Conference<h3>Background</h3><p dir="ltr">There is a lack of evidence regarding the economic impact of antimicrobial stewardship program (ASP).We sought to evaluate the cost-benefit of the mature ASP use compared to premature ASP use in the adults’ general medicine settings in Qatar. </p><h3>Methods</h3><p dir="ltr">Patient records were retrospectively reviewed during two periods: premature ASP (i.e. the 12 months following ASP implementation (May 2015-April 2016)), and mature ASP (i.e. the last 12 months of a 5-year ASP implementation in Hamad Medical Corporation (HMC) (February 2019-January 2020)). The economic benefit of the ASP maturity was calculated as the sum of the cost savings and the cost avoidance, minus the operational cost of the service.3 The cost savings were the reduced cost of therapy associated with an assumed reduction in defined daily dose and resource utilization because of the ASP maturity. Cost avoidance was the cost avoided by reducing length of hospitalization and adverse drug events. Operational costs included the monetary value of the time spent in data collection, clinical rounds, and committee meetings. A total of 500 patients were randomly included (250 in each cohort).</p><h3> Results</h3><p dir="ltr">The operational costs of the program decreased with maturity by cost savings of QAR125 per 100-patient beds per year. Antimicrobials use and resource utilization, and their associated costs, declined after the maturity of ASP (i.e. positive cost saving), with a cost saving of QAR 458 (US$ 125) per 100-patient beds per year, signifying a benefit of QAR 458 generated for each QAR 1 invested in the ASP service. The avoided cost was in negative, by QAR -4,807 per 100-patient beds, in favour of the premature period. Sensitivity analyses indicated a 100% probability that maturity is linked with a positive benefit-to-cost ratio (Figures 1 and 2).</p><h3>Conclusion</h3><p dir="ltr">We showed that substantial savings in healthcare costs can be achieved through the maturity of ASP, even when accounting for ASP operational costs.</p>2024-05-26T10:59:37ZTextConference contributioninfo:eu-repo/semantics/publishedVersiontextconference object10.57945/manara.25709292.v1https://figshare.com/articles/conference_contribution/Cost-Benefit_Analysis_of_Antimicrobial_Stewardship_Program_in_the_Adult_General_Medicine_Setting_in_Qatar/25709292CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/257092922024-05-26T10:59:37Z |
| spellingShingle | Cost-Benefit Analysis of Antimicrobial Stewardship Program in the Adult General Medicine Setting in Qatar Dina Abushanab (10696501) Biomedical and clinical sciences Clinical sciences Pharmacology and pharmaceutical sciences Economics Applied economics Antimicrobial Stewardship Cost-benefit General medicine Qatar Qatar Health Congress 2023 and the 3rd Qatar Public Health Conference |
| status_str | publishedVersion |
| title | Cost-Benefit Analysis of Antimicrobial Stewardship Program in the Adult General Medicine Setting in Qatar |
| title_full | Cost-Benefit Analysis of Antimicrobial Stewardship Program in the Adult General Medicine Setting in Qatar |
| title_fullStr | Cost-Benefit Analysis of Antimicrobial Stewardship Program in the Adult General Medicine Setting in Qatar |
| title_full_unstemmed | Cost-Benefit Analysis of Antimicrobial Stewardship Program in the Adult General Medicine Setting in Qatar |
| title_short | Cost-Benefit Analysis of Antimicrobial Stewardship Program in the Adult General Medicine Setting in Qatar |
| title_sort | Cost-Benefit Analysis of Antimicrobial Stewardship Program in the Adult General Medicine Setting in Qatar |
| topic | Biomedical and clinical sciences Clinical sciences Pharmacology and pharmaceutical sciences Economics Applied economics Antimicrobial Stewardship Cost-benefit General medicine Qatar Qatar Health Congress 2023 and the 3rd Qatar Public Health Conference |